Detalles de la búsqueda
1.
The STE20 kinase HGK is broadly expressed in human tumor cells and can modulate cellular transformation, invasion, and adhesion.
Mol Cell Biol
; 23(6): 2068-82, 2003 Mar.
Artículo
en Inglés
| MEDLINE | ID: mdl-12612079
2.
SU5416 and SU6668 attenuate the angiogenic effects of radiation-induced tumor cell growth factor production and amplify the direct anti-endothelial action of radiation in vitro.
Cancer Res
; 63(13): 3755-63, 2003 Jul 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-12839971
3.
The Met kinase inhibitor SU11274 exhibits a selective inhibition pattern toward different receptor mutated variants.
Oncogene
; 23(31): 5387-93, 2004 Jul 08.
Artículo
en Inglés
| MEDLINE | ID: mdl-15064724
4.
Potent and selective inhibitors of the Met [hepatocyte growth factor/scatter factor (HGF/SF) receptor] tyrosine kinase block HGF/SF-induced tumor cell growth and invasion.
Mol Cancer Ther
; 2(11): 1085-92, 2003 Nov.
Artículo
en Inglés
| MEDLINE | ID: mdl-14617781
5.
Improved effect of an antiangiogenic tyrosine kinase inhibitor (SU5416) by combinations with fractionated radiotherapy or low molecular weight heparin.
Neoplasia
; 5(2): 155-60, 2003.
Artículo
en Inglés
| MEDLINE | ID: mdl-12659688
6.
Voreloxin, a first-in-class anticancer quinolone derivative, acts synergistically with cytarabine in vitro and induces bone marrow aplasia in vivo.
Cancer Chemother Pharmacol
; 66(5): 881-8, 2010 Oct.
Artículo
en Inglés
| MEDLINE | ID: mdl-20058009
7.
SNS-314, a pan-Aurora kinase inhibitor, shows potent anti-tumor activity and dosing flexibility in vivo.
Cancer Chemother Pharmacol
; 65(4): 707-17, 2010 Mar.
Artículo
en Inglés
| MEDLINE | ID: mdl-19649632
8.
Adventitial microvessel formation after coronary stenting and the effects of SU11218, a tyrosine kinase inhibitor.
J Am Coll Cardiol
; 47(5): 1067-75, 2006 Mar 07.
Artículo
en Inglés
| MEDLINE | ID: mdl-16516095
Resultados
1 -
8
de 8
1
Próxima >
>>